Cardiff Oncology, Inc.
cardiffoncology.comWhat Do They Do?
Develops onvansertib, an oral cancer drug candidate, for use with standard treatments in patients with colorectal, pancreatic and other cancers.
10-K for FY2025, filed Feb 24, 2026
How Do They Make Money?
The company licenses legacy patent rights to healthcare companies, medical laboratories and biotechnology partners, earning upfront license fees and royalties tied to licensees’ sales or use; royalty income varies with licensee activity.
10-K for FY2025, filed Feb 24, 2026Total revenues were $0.6 million for the year ended December 31, 2025, as compared to $0.7 million for the same period in 2024. Revenues…View ↗
Royalty and License RevenuesView ↗
Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized…View ↗
$593K
-
10-K for FY2025, filed Feb 24, 2026
$593K ↗
Who Are Their Customers?
Licenses and sublicenses legacy patent rights to healthcare companies, medical laboratories and biotechnology partners.
10-K for FY2025, filed Feb 24, 2026Royalty and License RevenuesView ↗
Do Revenues Turn Into Profits?
No. It lost $45.9M in FY2025.
10-K for FY2025, filed Feb 24, 2026
−$49MView ↗
10-K for FY2025, filed Feb 24, 2026
−$45.9MView ↗
10-K for FY2025, filed Feb 24, 2026
−$38MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$9.2MView ↗
- ▼ −34% (Loss)
- vs −$13.9M in Q2 FY2025
-
Sep 14, 2026
Resolves onvansertib license dispute and revises license terms
Cardiff and Nerviano agreed to end the litigation and revise exclusivity, royalties, development payments and governance rights.
Sources
8-K, filed Sep 14, 2026
On September 14, 2026, Cardiff Oncology, Inc. (the “Company”) and Nerviano Medical Sciences, S.r.l. (“Nerviano”) entered into a…View ↗
-
May 29, 2026
Licensor gives notice to terminate the onvansertib license
Cardiff challenged the termination notice and said it would continue performing under the agreement.
Sources
8-K, filed May 29, 2026
As previously disclosed, on May 19, 2026, Cardiff Oncology, Inc. (the “Company”) filed a lawsuit against Nerviano Medical Sciences S.r.l.…View ↗
-
Apr 9, 2026
Appoints Mani Mohindru CEO and Josh Muntner CFO
Sources
8-K, filed Apr 9, 2026
On April 9, 2026, Cardiff Oncology, Inc. (the “Company”) announced that Josh Muntner has been appointed the Company’s Chief Financial…View ↗
Growing. Revenue grew 65% in 4 years, from $359K in FY2021 to $593K in FY2025, about 13% a year.
Colorectal program focus
The colorectal program has shifted from treatment after an earlier regimen to initial treatment of RAS-mutated metastatic colorectal cancer.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Feb 24, 2026CRDF-004 is a Phase 2 open-label, randomized multi-center clinical trial to assess the efficacy of two doses of onvansertib (20mg and 30mg)…View ↗
Pancreatic trial approach
A planned pancreatic study for people whose cancer progressed after earlier treatment was replaced by an investigator-led study combining onvansertib with the initial standard treatment.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Feb 24, 2026In February 2024, the FDA approved NALIRIFOX as a first-line treatment option for mPDAC. As a result, we are currently supporting an…View ↗
Additional cancer indication
The latest business description adds chronic myelomonocytic leukemia as an area of investigation alongside pancreatic, lung and triple-negative breast cancers.
10-K for FY2022, filed Mar 2, 2023We and certain investigators are currently conducting signal-finding clinical trials to explore the treatment opportunity for onvansertib…View ↗
Who Do They Compete With?
Competes with Boehringer Ingelheim, Cyclacel, Amgen, Pfizer, BMS, and Summit Therapeutics
10-K for FY2025, filed Feb 24, 2026The PLK inhibitor that reached the latest stage of clinical development (Phase 3), is volasertib, a pan-PLK inhibitor developed by…View ↗
Loading...
